TY  - JOUR
A1  - Lehrieder, Dominik
A1  - Zapantis, Nikolaos
A1  - Pham, Mirko
A1  - Schuhmann, Michael Klaus
A1  - Haarmann, Axel
T1  - Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
T2  - Frontiers in Neurology
N2  - Background 
Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.

Case presentation 
We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.

Conclusion 
Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.
KW  - NMOSD
KW  - inebilizumab
KW  - AQP4
KW  - longitudinally extensive transverse myelitis
KW  - optic neuritis
KW  - case report
KW  - CD19
KW  - seronegative
Y1  - 2023
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/35403
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-354031
VL  - 14
ER  -